Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Update

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,560,000 shares, an increase of 12.7% from the December 15th total of 3,160,000 shares. Based on an average daily trading volume, of 2,410,000 shares, the days-to-cover ratio is presently 1.5 days.

Insider Buying and Selling at Aclaris Therapeutics

In other news, Director Anand Mehra acquired 666,666 shares of Aclaris Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average cost of $2.25 per share, for a total transaction of $1,499,998.50. Following the completion of the purchase, the director now directly owns 710,030 shares in the company, valued at $1,597,567.50. This trade represents a 1,537.37 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.40% of the stock is currently owned by company insiders.

Institutional Trading of Aclaris Therapeutics

Institutional investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Aclaris Therapeutics in the second quarter valued at approximately $119,000. Assenagon Asset Management S.A. acquired a new stake in Aclaris Therapeutics in the third quarter valued at approximately $214,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Aclaris Therapeutics by 187.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock valued at $382,000 after purchasing an additional 216,826 shares during the period. Geode Capital Management LLC grew its holdings in Aclaris Therapeutics by 9.3% in the third quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock valued at $974,000 after purchasing an additional 72,309 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Aclaris Therapeutics in the third quarter valued at approximately $1,053,000. 98.34% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on ACRS shares. StockNews.com upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. Leerink Partnrs upgraded Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 19th. Cantor Fitzgerald upgraded Aclaris Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Wednesday, November 20th. Jefferies Financial Group upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and raised their price objective for the stock from $2.00 to $7.00 in a research note on Tuesday, November 19th. Finally, BTIG Research raised Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 target price on the stock in a report on Tuesday, November 19th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Aclaris Therapeutics has a consensus rating of “Buy” and a consensus price target of $11.00.

Aclaris Therapeutics Stock Up 2.4 %

Aclaris Therapeutics stock opened at $2.57 on Friday. The firm has a market cap of $183.58 million, a price-to-earnings ratio of -4.94 and a beta of 0.54. Aclaris Therapeutics has a 52 week low of $0.95 and a 52 week high of $5.17. The business’s 50-day moving average price is $3.09 and its 200 day moving average price is $1.93.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. The business had revenue of $4.35 million during the quarter, compared to analyst estimates of $8.31 million. Equities analysts expect that Aclaris Therapeutics will post -0.81 EPS for the current year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.